Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
Molnupiravir (Lagevrio) is an oral antiviral for treating patients with COVID-19 in the community.
Access criteria are the same as for nirmatrelvir/ritonavir (Paxlovid). Molnupiravir should only be used where nirmatrelvir/ritonavir is clinically inappropriate, as trial data suggest molnupiravir is much less effective. Read our article for details.
Log in to EPiC and view your report by 31 July 2022 and go into the draw to win a $2000 travel voucher.
Accessing your report is free and easy; log in with your New Zealand Doctor, Pharmacy Today, or He Ako Hiringa account. Or sign up for your free account at epic.akohiringa.co.nz.
Explore your prescribing further with EPiC Reflect Annual Report. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.
Nirmatrelvir with ritonavir (Paxlovid), a new oral antiviral medicine for adults with COVID-19, is now available for community use. In people at higher risk of severe illness from COVID-19, treatment with Paxlovid has been shown to reduce the incidence of hospitalisation or death. However, for certain patients it will not be safe or appropriate to use Paxlovid. Prescriptions must be endorsed to confirm patients meet Pharmac access criteria.
This workbook consists of introductory reading and five distinct modules that encourage you to reflect on your CVD risk assessment and management practices, risk communication, cultural safety, and your engagement with young adult Māori and Pacific patients.
Explore your prescribing further with EPiC Reflect Gout. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.
Explore your prescribing further with EPiC Reflect Diabetes. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.
This short video explores what patients think about the move to Amgevita. We spoke to a group of seven New Zealanders living with arthritis to find out how they feel about changing from the biological reference medicine, Humira, to the new biosimilar medicine, Amgevita.
Since 1 April 2022, the oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) has been listed on the Pharmaceutical Schedule for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria and to comprehensive drug interaction guidance.
The current primary care CVD management guidance strongly recommends aggressive risk management and lifestyle modification in patients with pre-existing CVD or an equivalent CVD risk. Significant opportunities to improve use of CVD medicines remain, particularly for Māori and Pacific peoples who lose 2.6–2.8 times more years to CVD events relative to non-Māori/non-Pacific peoples.
Looking for up-to-date information on gout or biological medicines? You can find it in our resource hubs. We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need - articles, datasheets, videos, podcasts, and more.
Explore our range of resources, listed by the name of the medicine on which they focus.